Roivant files pro forma financials for $7.1B Telavant sale to Roche; gain of $5.3B

Roivant Sciences Ltd.

Roivant sold its 75% stake in Telavant to Roche for ~$7.1B cash plus $150M milestone for Phase 3 trial initiation.
Pro forma cash and cash equivalents at Sep 30, 2023: $6.6B, up from $1.4B historical.
Pro forma net income attributable to Roivant for FY Mar 2023: $4.3B vs historical net loss of $1.1B.
Pro forma net loss for H1 Sep 2023: $552M vs historical loss of $596M; reduction from eliminated Telavant R&D.
Transaction accounted for as sale of nonfinancial assets; $5.3B gain recognized.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.